Cardior Pharmaceuticals
Hanover
About Cardior Pharmaceuticals
Cardior Pharmaceuticals is a biotechnology company that engages in the development of non-coding RNA based therapeutics for the treatment and prevention of heart disease. It focuses on developing CDR-132X, an oligonucleotide-based inhibitor of a molecular master switch (microRNA) controlling pathological alterations of the heart following stress or injury. Cardior Pharmaceuticals is a planned academic spin-off developing new therapeutics for the treatment and prevention of heart disease - the number one cause of death in the western world.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $92.8M
- Funding stage: M&A
- Last round: Series B (Aug 2021)
- Website: cardior.de
- Phone: +49 (0)511-33 85 99 30
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/cardior-pharmaceuticals-117650 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.